Elevated umbilical artery systolic/diastolic ratio in the absence of fetal growth restriction.

PURPOSE: To evaluate whether patients with isolated elevation of umbilical artery (UA) systolic/diastolic (S/D) ratio are at increased risk for adverse perinatal outcome. METHODS: This is a retrospective cohort study of 330 patients who underwent routine evaluation at our maternal fetal medicine center. We regularly perform UA S/D ratio analysis with every third trimester sonogram. All identified patients were included and divided into four groups based on estimated fetal weight (EFW) and UA S/D ratio. Perinatal outcome was compared between the groups. RESULTS: Regardless of the EFW, fetuses with persistent elevated UA S/D ratio showed significantly more preterm deliveries (p < .001), neonatal intensive care unit (NICU) admissions (p < .001), longer stay in the NICU (p < .001) and lower birth weight (p < .001) relative to controls. Stepwise logistic regression analysis demonstrated that being a member in any study group significantly and independently predicted birth weight less than the 10th percentile and preterm delivery. Patients with persistently elevated S/D ratio were significantly and independently from other factors, more likely to have a newborn admitted to the NICU. CONCLUSION: Our results indicate a suboptimal perinatal outcome in all pregnancies with an elevated UA S/D ratio. These fetuses may benefit from intensive monitoring.

HELLP syndrome: a rare, early presentation at 17 weeks of gestation.

BACKGROUND: The occurrence of hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome before 20 weeks of gestation is extremely rare. This condition has been reported in only few cases, and always in conjunction with other comorbidities such as fetal triploidy and the antiphospholipid syndrome. CASE: A 24-year-old woman was admitted at 15 weeks and 3 days of gestation with uncontrollable hypertension and proteinuria. An extensive workup did not reveal any underlying medical or obstetric conditions. Within 11 days of admission her condition deteriorated and the diagnosis of severe HELLP syndrome was supported by the findings of hemolysis, elevated liver enzymes, and severe thrombocytopenia, all of which resolved after termination of the pregnancy. CONCLUSION: Clinicians should consider the diagnosis of HELLP syndrome in women presenting with clinical manifestations or laboratory abnormalities consistent with this diagnosis, even before 20 weeks of gestation.

The risk of a major trisomy in fetuses with pyelectasis: the impact of an abnormal maternal serum screen or additional sonographic markers.

OBJECTIVE: This study was undertaken to evaluate the contribution of either an abnormal second-trimester maternal serum screen or the presence of additional sonographic markers of aneuploidy to the risk of a major trisomy (13, 18, and 21) in fetuses with pyelectasis. STUDY DESIGN: A retrospective review of a large amniocentesis database was performed. Specimens obtained after the sonographic detection of fetal pyelectasis were eligible for analysis. Age-matched women who underwent amniocentesis solely for maternal anxiety or advanced maternal age served as controls. RESULTS: 760,495 amniocentesis specimens were analyzed. Fetal pyelectasis was detected in 671 cases. Pyelectasis, with either a single or multiple additional sonographic markers, was associated with an 8-fold and 62-fold increase in the prevalence of major trisomies (odds ratio = 7.7, 95% CI = 1.2-32.6, P = 0.02) and (odds ratio = 61.9, 95% CI = 13.2-144.6, P < .001), respectively. Pyelectasis with an abnormal maternal serum screen, with or without additional sonographic markers, was associated with a 32-fold and a 205-fold increase in major trisomies (odds ratio = 32.2, 95% CI = 5.3-94.8, P < .001) and (odds ratio = 205.8, 95% CI = 37.9-427.6, P < .001), respectively. CONCLUSION: In fetuses with pyelectasis, the presence of additional sonographic markers or an abnormal maternal serum screen significantly increases the risk of trisomy 13, 18, and 21.

The impact of maternal age, body mass index and maternal weight gain on the glucose challenge test in pregnancy.

OBJECTIVE: The aim of this study was to determine whether maternal age, prepregnancy and mid-trimester body mass index (BMI), or excessive mid-pregnancy weight gain predict abnormal glucose challenge test (GCT) results. METHODS: A retrospective chart review of 75 consecutive singleton pregnancies was performed. Patients were screened at 24-28 weeks of gestation with a 50-g oral GCT. Prepregnancy BMI and pregnancy weight gain up to the time of GCT testing, as well as other demographic data, were recorded. Statistical analysis included regression analysis and Student's t-test, receiver-operator characteristic curve and multivariate logistic regression. RESULTS: Maternal age and prepregnancy and mid-trimester BMI were significantly higher in women with an abnormal GCT (p<0.05). A direct correlation was found between these parameters and GCT results (R(2)=0.08, R(2)=0.102 and R(2)=0.116, respectively; p<0.05). Mid-trimester maternal BMI of >or=30 kg/m(2) and maternal age >or=32 years are the optimal predictors of abnormal GCT results. CONCLUSIONS: Mid-trimester maternal BMI of >or=30 kg/m(2) and maternal age >or=32 years are useful predictors of abnormal GCT results. We suggest that these factors should also be considered when selective screening for gestational diabetes mellitus is practiced.

Fetal pyelectasis: does fetal gender modify the risk of major trisomies?

OBJECTIVE: Several studies have noted an increased prevalence of pyelectasis in male fetuses. It is speculated that pyelectasis represents a normal physiologic variant in males, whereas its presence in females indicates an increased risk of chromosomal abnormalities. Thus, we sought to investigate the association between fetal gender and the risk of major trisomies in fetuses with pyelectasis. METHODS: Retrospective analysis of a Genzyme Genetics amniocentesis database (1995 to 2004) was performed. Specimens obtained after an ultrasonographic finding of pyelectasis were eligible for analysis. The prevalence of major trisomies (trisomy 13, 18, or 21) in male and female fetuses with pyelectasis was compared using binomial distribution. RESULTS: A total of 760,495 amniocentesis specimens were analyzed. Fetal pyelectasis was reported in 671 cases. A male predominance, with a male-to-female ratio of 2.14:1 (457 compared with 214) was statistically significant (P < .001). A major trisomy was detected in 26 male fetuses (5.7%): 18 cases of trisomy 21, 2 cases of trisomy 18, and 6 cases of trisomy 13. Nine female fetuses had a major trisomy (4.2%): 6 cases of trisomy 21 and 3 cases of trisomy 13. There was no significant difference in the overall prevalence of trisomies between male and female fetuses (P = .14). CONCLUSION: We concur with previous studies documenting a higher prevalence of pyelectasis in male fetuses. In addition, our results indicate that the prevalence of major trisomies among fetuses with pyelectasis is unlikely to be dependent on fetal gender. Thus, counseling patients with regard to the genetic implications of fetal pyelectasis should be gender independent. LEVEL OF EVIDENCE: II-2.

The association of maternal BMI with fetal echogenic intracardiac foci and echogenic bowel.

OBJECTIVES: To evaluate the impact of maternal body mass index (BMI) as well as maternal ethnicity on the detection of either echogenic intra-cardiac focus (EIF) or echogenic bowel (EB). METHODS: This prospective study identified 74 uncomplicated singleton fetuses in which EIF and/or EB were detected between 18 and 21 weeks of gestation (i.e. study group). Seventy four consecutively scanned fetuses without EIF or EB, at the same gestational age, were selected as controls. The differences in maternal BMI and maternal ethnicity were compared between the two groups using the chi(2) test, Fisher's exact test, and the Student t-test. A multivariable logistic regression model was constructed to control for confounders. Odds ratios (OR) and their 95% confidence interval (CI) were computed. RESULTS: The mean maternal BMI was significantly lower in the study group as compared to controls (22.9 +/- 3.1 vs. 28.0 +/- 7.5 kg/m(2), respectively; p < 0.0001). Patients with fetal EIF and/or EB were significantly more likely to be Asians (20.3% vs. 5.4%, OR = 4.5; 95% CI 1.3-16.9). Using a multivariable analysis, controlling for ethnicity, the association between maternal BMI and fetal EIF or EB remained significant (OR = 0.83; 95% CI 0.76-0.91). However, based on this model Asian ethnicity was not an independent risk factor for the detection of EIF and/or EB (OR = 2.6; 95% CI 0.8-8.9). CONCLUSIONS: Our data suggests an inverse relationship between the maternal BMI and the detection of fetal EIF and/or EB. Moreover, it appears that low maternal BMI, and not Asian ethnicity, is an independent risk factor for the detection of these echogenic fetal findings.

Advanced maternal age as a sole indication for genetic amniocentesis; risk-benefit analysis based on a large database reflecting the current common practice.

AIMS: Recent advances in prenatal screening, including first and second trimester genetic screening as well as targeted sonography, have significantly improved the detection of trisomy 21. Therefore, several investigators have questioned the validity of recommending genetic amniocentesis to all women who are 35 years or older at delivery. Thus, we sought to investigate the risks and benefits associated with performing genetic amniocentesis in women whose sole indication for testing was advanced maternal age (AMA). METHODS: A retrospective review of a Genzyme Genetics amniocentesis database (January 2006-December 2006) was performed. All specimens obtained from women of AMA as the sole indication were eligible for analysis. The amniocentesis-related potential fetal loss was calculated based on the traditional fetal loss rate of 1/200 as well as the recently published loss rate of 1/1600 procedures. Risk-benefit analysis was performed by comparing the number of trisomy 21 fetuses identified within the AMA group to the potential number of amniocentesis-related fetal losses within this group. RESULTS: A total of 87,241 amniocentesis specimens were processed during the study period. AMA was the sole indication for genetic amniocentesis in 43,303 cases which formed the study group. In 399 (0.92%) of these cases, a trisomy 21 was identified. Assuming an amniocentesis related fetal loss rates of 1/200 or 1/1600; 217 or 27 fetal losses would have been expected, respectively. CONCLUSIONS: Our analysis suggests that the benefit of genetic amniocentesis for the sole indication of AMA far outweighs the potential amniocentesis-related fetal loss rate, regardless of the actual rate one considers.